One year after the Food and Drug Administration launched a voluntary pilot program to release clinical study reports, which are summaries of clinical trial data, only one company has provided any information about a drug. As a result, a group of academics is concerned the effort has stalled and is calling on the agency to make such disclosures mandatory.

Clinical study reports help form the basis for regulatory approval decisions, but disclosure has long been a flashpoint among researchers and drug makers, prompting heated debate about patient privacy, trade secrets, and improving medical research. However, regulators in other countries had taken steps to disclose these reports and the FDA touted the program as its own bid to provide greater transparency.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy